For the quarter ending 2025-09-30, CNTA had $6,569K increase in cash & cash equivalents over the period. -$58,546K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net loss | -54,891 | -50,343 | -26,135 | -111,329 |
| Share-based compensation expense | 7,194 | 7,949 | 7,883 | 8,328 |
| Loss on extinguishment of debt | - | - | - | -34,097 |
| Depreciation and amortization | 237 | 226 | 217 | 230 |
| Amortization of discount of marketable securities | 114 | 53 | 2,082 | - |
| Amortization of debt issuance costs and exit fee of long-term debt | 271 | 293 | 312 | - |
| Change in fair value of financial instruments | - | 0 | 0 | -300 |
| Change in deferred taxes | 255 | 1,026 | 995 | 398 |
| Tax incentive receivable | 9,983 | -10,731 | 4,283 | 12,095 |
| Prepaid expenses and other assets | 3,935 | -4,701 | 2,676 | -4,489 |
| Operating leases, net | 63 | 63 | 65 | 73 |
| Accounts payable | 3,280 | 177 | -2,095 | 143 |
| Accrued expenses and other liabilities | -689 | 2,881 | -29,550 | 32,734 |
| Other, net | -103 | - | 103 | -168 |
| Net cash used in operating activities | -58,312 | -22,452 | -57,246 | -42,800 |
| Purchases of investments in marketable securities | 45,512 | 83,061 | 297,476 | 0 |
| Proceeds from redemption of investments in marketable securities | 107,691 | 43,233 | 75,088 | 25,000 |
| Purchases of property and equipment | 234 | 126 | - | 0 |
| Net cash (used in) provided by investing activities | 61,945 | -39,954 | -222,388 | 25,000 |
| Proceeds from issuance of shares under atm program, net of issuance costs-Underwriter Offering | 0 | 0 | - | -30 |
| Proceeds from issuance of shares under atm program, net of issuance costs-At The Market Program | 0 | 0 | 6,109 | 0 |
| Repayment of debt | - | - | - | 110,097 |
| Proceeds from issuance of debt, net of issuance costs | - | - | - | 109,335 |
| Proceeds from option exercises | 3,562 | 1,705 | 1,763 | 5,342 |
| Payment of employee withholding taxes related to withheld shares for stock based compensation plans | 125 | 4,490 | - | - |
| Other, net | 0 | 4,390 | -4,786 | -1,587 |
| Net cash provided by financing activities | 3,437 | 1,605 | 3,086 | 2,963 |
| Effect of exchange rate on cash and cash equivalents | -501 | -113 | -1,517 | 3,032 |
| Net decrease in cash and cash equivalents | 6,569 | -60,914 | -278,065 | -11,805 |
| Cash and cash equivalents at beginning of period | 44,242 | 105,156 | 383,221 | 395,026 |
| Cash and cash equivalents at end of period | 50,811 | 44,242 | 105,156 | 383,221 |
Centessa Pharmaceuticals plc (CNTA)
Centessa Pharmaceuticals plc (CNTA)